Amsterdam

• Comparison of targeted radiotherapy with and without short-term hormonal treatment (6 months) Ended recruitment
  2024-511252-41-00 5 2024-07-30 Patients with biochemical recurrence after primary treatment of prosta
• A study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE-T) Ended recruitment
  2024-512747-23-00 5 2024-07-30 Transfusion-Dependent Alpha- or Beta-Thalassemia
• Personalized extended interval dosing of natalizumab in relapsing remitting multiple sclerosis (NEXT-MS) Ended recruitment
  2024-513105-31-00 6 2024-07-30 Multiple Sclerosis
• DUTCH-WAIST Ended recruitment
  2022-501392-81-00 6 2024-07-25 Obesity
• HOVON 169 CAD: Phase II trial of Zanubrutinib in primary Cold Agglutinin Disease. CaZa study Ended recruitment
  2023-505746-25-00 4 2024-07-16 Cold agglutinin disease
• [18F]F-FAPI PET-CT to Identify Carcinoma of Unknown Primary origin Ended recruitment
  2023-505592-69-00 5 2024-07-12 Carcinoma of Unknown Primary
• An Open-label Extension Study Evaluating the Long-term Safety and Efficacy of Seralutinib Orally Inhaled for the Treatment of Pulmonary Arte … Ended recruitment
  2023-506334-75-00 5 2024-07-12 Pulmonary Arterial Hypertension
• A Phase 3 Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants with Early Alzhei … Ended recruitment
  2023-508306-15-00 5 2024-06-26 Alzheimer’s Disease
• TGF‐β And PDL‐1 inhibition with Bintrafusp alfa in Esophageal Squamous Cell carcinoma combined with chemoradiation TheRapY (TAPESTRY) Ended recruitment
  2023-503312-32-00 4 2024-06-24 Esophageal squamous cell carcinoma
• A study evaluating the safety and efficacy of GLPG5101 (19CP02) in subjects with non-Hodgkin lymphoma Ended recruitment
  2022-502661-23-00 7 2024-06-11 Relapsed/refractory B-cell non-Hodgkin lymphoma
• A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascu … Ended recruitment
  2022-502781-24-01 5 2024-06-05 ASCVD - Atherosclerotic Cardiovascular Disease
• Evaluating T Cell Changes and Activation in Cancer Patient Using Two PET Tracers (iRelate) Ended recruitment
  2023-509486-20-00 10 2024-05-29 Breast cancer
• The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-OUTCOMES) Ended recruitment
  2023-508630-34-00 5 2024-05-28 Overweight
• Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change i … Ended recruitment
  2023-506906-38-00 5 2024-05-23 Follicular Lymphoma
• A trial to find out how safe REGN7075 is and how well it works in combination with cemiplimab for participants with advanced cancers Ended recruitment
  2022-501234-37-00 7 2024-05-07 Solid Tumours
• Phase III Trial of Volrustomig (MEDI5752) in Combination with Carboplatin plus Pemetrexed vs. Investigator’s Choice of the Standard of Care … Ended recruitment
  2023-503231-17-00 5 2024-04-26 Unresectable Pleural Mesothelioma
• Selective Treatment of Oral Povorcitinib in Vitiligo Study 1 (STOP-V1) Ended recruitment
  2023-505782-86-00 5 2024-04-23 Vitiligo
• A study to assess adverse events and effectiveness of upadacitinib oral tablets in adult and adolescent participants with vitiligo. Ended recruitment
  2023-506195-27-00 5 2024-04-05 non-segmental vitiligo
• A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab i … Ended recruitment
  2023-506948-17-00 5 2024-04-05 Previously Untreated Chronic Lymphocytic Leukemia
• IAVI C110 HIV Vaccine Trial Ended recruitment
  2023-508157-15-01 1 2024-03-19 Human Immunodeficiency Virus (HIV)
• MK-2870 in Post Platinum and Post Immunotherapy Endometrial Cancer Ended recruitment
  2023-504816-14-00 5 2024-03-08 Endometrial cancer
• A study of zipalertinib and chemotherapy compared with chemotherapy alone in patients with advanced Non-Small Cell Lung Cancer with Epiderma … Ended recruitment
  2023-503575-21-00 5 2024-01-23 Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
• NAC Attack, A Phase III, Multicenter, Randomized, Parallel, Double Masked, Placebo-Controlled Study Evaluating the Efficacy and Safety of Or … Ended recruitment
  2022-501438-46-00 5 2024-01-22 Retinitis Pigmentosa
• Aspirin to prevent cardiovascular events in patients with pneumonia or influenza Ended recruitment
  2023-504553-12-01 6 2023-12-27 Influenza

Showing 673–696 of 1,112 trials